Regulatory update for REZONIC (casopitant mesylate)
GlaxoSmithKline confirmed that it has received a complete response letterfrom the FDA related to the application for casopitant. The company is reviewing this letter and will engage with the FDA to determine appropriate next steps. one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. [more...]
|
|
|
